schliessen

Filtern

 

Bibliotheken

The − 11391 G/A Polymorphism of the Adiponectin Gene Promoter is Associated with Metabolic Syndrome Traits and the Outcome of an Energy-restricted Diet in Obese Subjects

Abstract Adiponectin is an adipose tissue–specific hormone that is commonly decreased in obese subjects. Furthermore, single-nucleotide polymorphisms (SNPs) of the adiponectin gene have been associated with metabolic phenotypes. The present study investigated whether the adiponectin gene promoter va... Full description

Journal Title: Hormone and metabolic research 2009, Vol.41(1), pp.55-61
Main Author: Goyenechea, E, J
Other Authors: Collins, L, B , Parra, D, D , Abete, I, A , Crujeiras, A, A , O’dell, S, A , Martínez, J, A
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0018-5043 ; E-ISSN: 1439-4286 ; DOI: 10.1055/s-0028-1087204
Link: dx.doi.org/10.1055/s-0028-1087204
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: thieme_articles10.1055/s-0028-1087204
title: The − 11391 G/A Polymorphism of the Adiponectin Gene Promoter is Associated with Metabolic Syndrome Traits and the Outcome of an Energy-restricted Diet in Obese Subjects
format: Article
creator:
  • Goyenechea, E, J
  • Collins, L, B
  • Parra, D, D
  • Abete, I, A
  • Crujeiras, A, A
  • O’dell, S, A
  • Martínez, J, A
subjects:
  • Adiponectin
  • Insulin Resistance
  • Metabolic Syndrome
  • Obesity Therapy
  • Polymorphism
  • Weight Loss
  • Weight Regulation
ispartof: Hormone and metabolic research, 2009, Vol.41(1), pp.55-61
description: Abstract Adiponectin is an adipose tissue–specific hormone that is commonly decreased in obese subjects. Furthermore, single-nucleotide polymorphisms (SNPs) of the adiponectin gene have been associated with metabolic phenotypes. The present study investigated whether the adiponectin gene promoter variant −11391 G/A (rs17300539) could predict the risk of developing traits characterizing the metabolic syndrome (MetS) and the impact of weight management. The −11391 G/A SNP was genotyped in 180 Spanish volunteers (BMI: 31.4±3.2 kg/m 2 ; age: 35±5 years). Clinical measurements were determined at baseline, following an 8-week low-calorie diet (LCD), and at 32 and 60 weeks. At baseline, the GG genotype was associated with higher HOMA-IR, insulin and triacylglyceride concentrations than other genotypes (p0.05). By 32 weeks after dietary therapy (n=84), GG carriers had recovered the risk of metabolic comorbidities (OR: 2.420, p=0.043). This risk was even more evident after 60 weeks (OR: 2.875, p=0.014). These data show an increased risk of insulin resistance and MetS complications in obese subjects of the −11391 GG genotype. The risk was markedly reduced during an energy-restricted diet, but was not sustained. Carriage of the A allele therefore confers protection from weight regain, and the effect is particularly evident 32–60 weeks after the dietary intervention, when improvement in GG subjects had disappeared.
language: eng
source:
identifier: ISSN: 0018-5043 ; E-ISSN: 1439-4286 ; DOI: 10.1055/s-0028-1087204
fulltext: fulltext
issn:
  • 0018-5043
  • 00185043
  • 1439-4286
  • 14394286
url: Link


@attributes
ID707081516
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1055/s-0028-1087204
sourceidthieme_articles
recordidTN_thieme_articles10.1055/s-0028-1087204
sourceformatXML
sourcesystemPC
pqid66727097
display
typearticle
titleThe − 11391 G/A Polymorphism of the Adiponectin Gene Promoter is Associated with Metabolic Syndrome Traits and the Outcome of an Energy-restricted Diet in Obese Subjects
creatorGoyenechea, E, J ; Collins, L, B ; Parra, D, D ; Abete, I, A ; Crujeiras, A, A ; O’dell, S, A ; Martínez, J, A
ispartofHormone and metabolic research, 2009, Vol.41(1), pp.55-61
identifier
subjectAdiponectin ; Insulin Resistance ; Metabolic Syndrome ; Obesity Therapy ; Polymorphism ; Weight Loss ; Weight Regulation
descriptionAbstract Adiponectin is an adipose tissue–specific hormone that is commonly decreased in obese subjects. Furthermore, single-nucleotide polymorphisms (SNPs) of the adiponectin gene have been associated with metabolic phenotypes. The present study investigated whether the adiponectin gene promoter variant −11391 G/A (rs17300539) could predict the risk of developing traits characterizing the metabolic syndrome (MetS) and the impact of weight management. The −11391 G/A SNP was genotyped in 180 Spanish volunteers (BMI: 31.4±3.2 kg/m 2 ; age: 35±5 years). Clinical measurements were determined at baseline, following an 8-week low-calorie diet (LCD), and at 32 and 60 weeks. At baseline, the GG genotype was associated with higher HOMA-IR, insulin and triacylglyceride concentrations than other genotypes (p<0.05) and was also related with a higher risk of insulin resistance (OR: 2.437, p=0.025) and MetS clinical manifestations (OR: 3.236, p=0.003). Following the LCD, the increased risk in GG subjects compared with others disappeared (p>0.05). By 32 weeks after dietary therapy (n=84), GG carriers had recovered the risk of metabolic comorbidities (OR: 2.420, p=0.043). This risk was even more evident after 60 weeks (OR: 2.875, p=0.014). These data show an increased risk of insulin resistance and MetS complications in obese subjects of the −11391 GG genotype. The risk was markedly reduced during an energy-restricted diet, but was not sustained. Carriage of the A allele therefore confers protection from weight regain, and the effect is particularly evident 32–60 weeks after the dietary intervention, when improvement in GG subjects had disappeared.
languageeng
source
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Udx.doi.org/10.1055/s-0028-1087204$$EView_record_in_Thieme_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Goyenechea, E, J
1Collins, L, B
2Parra, D, D
3Abete, I, A
4Crujeiras, A, A
5O’dell, S, A
6Martínez, J, A
titleThe − 11391 G/A Polymorphism of the Adiponectin Gene Promoter is Associated with Metabolic Syndrome Traits and the Outcome of an Energy-restricted Diet in Obese Subjects
descriptionAbstract Adiponectin is an adipose tissue–specific hormone that is commonly decreased in obese subjects. Furthermore, single-nucleotide polymorphisms (SNPs) of the adiponectin gene have been associated with metabolic phenotypes. The present study investigated whether the adiponectin gene promoter variant −11391 G/A (rs17300539) could predict the risk of developing traits characterizing the metabolic syndrome (MetS) and the impact of weight management. The −11391 G/A SNP was genotyped in 180 Spanish volunteers (BMI: 31.4±3.2 kg/m 2 ; age: 35±5 years). Clinical measurements were determined at baseline, following an 8-week low-calorie diet (LCD), and at 32 and 60 weeks. At baseline, the GG genotype was associated with higher HOMA-IR, insulin and triacylglyceride concentrations than other genotypes (p<0.05) and was also related with a higher risk of insulin resistance (OR: 2.437, p=0.025) and MetS clinical manifestations (OR: 3.236, p=0.003). Following the LCD, the increased risk in GG subjects compared with others disappeared (p>0.05). By 32 weeks after dietary therapy (n=84), GG carriers had recovered the risk of metabolic comorbidities (OR: 2.420, p=0.043). This risk was even more evident after 60 weeks (OR: 2.875, p=0.014). These data show an increased risk of insulin resistance and MetS complications in obese subjects of the −11391 GG genotype. The risk was markedly reduced during an energy-restricted diet, but was not sustained. Carriage of the A allele therefore confers protection from weight regain, and the effect is particularly evident 32–60 weeks after the dietary intervention, when improvement in GG subjects had disappeared.
subject
0Adiponectin
1Insulin Resistance
2Metabolic Syndrome
3Obesity Therapy
4Polymorphism
5Weight Loss
6Weight Regulation
general
0English
1Thieme eJournals
210.1055/s-0028-1087204
3Thieme Publishing Group
sourceidthieme_articles
recordidthieme_articles10.1055/s-0028-1087204
issn
00018-5043
100185043
21439-4286
314394286
rsrctypearticle
creationdate2009
addtitleHormone And Metabolic Research
searchscopethieme_journals
scopethieme_journals
lsr30VSR-Enriched:[pages, pqid]
sort
titleThe − 11391 G/A Polymorphism of the Adiponectin Gene Promoter is Associated with Metabolic Syndrome Traits and the Outcome of an Energy-restricted Diet in Obese Subjects
authorGoyenechea, E, J ; Collins, L, B ; Parra, D, D ; Abete, I, A ; Crujeiras, A, A ; O’dell, S, A ; Martínez, J, A
creationdate20090100
facets
frbrgroupid8280406406212656090
frbrtype5
languageeng
creationdate2009
topic
0Adiponectin
1Insulin Resistance
2Metabolic Syndrome
3Obesity Therapy
4Polymorphism
5Weight Loss
6Weight Regulation
collectionThieme eJournals
prefilterarticles
rsrctypearticles
creatorcontrib
0Goyenechea, E, J
1Collins, L, B
2Parra, D, D
3Abete, I, A
4Crujeiras, A, A
5O’dell, S, A
6Martínez, J, A
jtitleHormone And Metabolic Research
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Goyenechea
1Collins
2Parra
3Abete
4Crujeiras
5O’Dell
6Martínez
aufirst
0E.
1L.
2D.
3I.
4A.
5S.
6J.
auinitm
0J.
1B.
2D.
3A.
au
0Goyenechea, E, J
1Collins, L, B
2Parra, D, D
3Abete, I, A
4Crujeiras, A, A
5O’dell, S, A
6Martínez, J, A
atitleThe − 11391 G/A Polymorphism of the Adiponectin Gene Promoter is Associated with Metabolic Syndrome Traits and the Outcome of an Energy-restricted Diet in Obese Subjects
jtitleHormone And Metabolic Research
risdate200901
volume41
issue1
spage55
epage61
issn0018-5043
eissn1439-4286
genrearticle
ristypeJOUR
abstractAdiponectin is an adipose tissue–specific hormone that is commonly decreased in obese subjects. Furthermore, single-nucleotide polymorphisms (SNPs) of the adiponectin gene have been associated with metabolic phenotypes. The present study investigated whether the adiponectin gene promoter variant −11391 G/A (rs17300539) could predict the risk of developing traits characterizing the metabolic syndrome (MetS) and the impact of weight management. The −11391 G/A SNP was genotyped in 180 Spanish volunteers (BMI: 31.4±3.2 kg/m2; age: 35±5 years). Clinical measurements were determined at baseline, following an 8-week low-calorie diet (LCD), and at 32 and 60 weeks. At baseline, the GG genotype was associated with higher HOMA-IR, insulin and triacylglyceride concentrations than other genotypes (p<0.05) and was also related with a higher risk of insulin resistance (OR: 2.437, p=0.025) and MetS clinical manifestations (OR: 3.236, p=0.003). Following the LCD, the increased risk in GG subjects compared with others disappeared (p>0.05). By 32 weeks after dietary therapy (n=84), GG carriers had recovered the risk of metabolic comorbidities (OR: 2.420, p=0.043). This risk was even more evident after 60 weeks (OR: 2.875, p=0.014). These data show an increased risk of insulin resistance and MetS complications in obese subjects of the −11391 GG genotype. The risk was markedly reduced during an energy-restricted diet, but was not sustained. Carriage of the A allele therefore confers protection from weight regain, and the effect is particularly evident 32–60 weeks after the dietary intervention, when improvement in GG subjects had disappeared. Adiponectin is an adipose tissue–specific hormone that is commonly decreased in obese subjects. Furthermore, single-nucleotide polymorphisms (SNPs) of the adiponectin gene have been associated with metabolic phenotypes. The present study investigated whether the adiponectin gene promoter variant −11391 G/A (rs17300539) could predict the risk of developing traits characterizing the metabolic syndrome (MetS) and the impact of weight management. The −11391 G/A SNP was genotyped in 180 Spanish volunteers (BMI: 31.4±3.2 kg/m 2 ; age: 35±5 years). Clinical measurements were determined at baseline, following an 8-week low-calorie diet (LCD), and at 32 and 60 weeks. At baseline, the GG genotype was associated with higher HOMA-IR, insulin and triacylglyceride concentrations than other genotypes (p<0.05) and was also related with a higher risk of insulin resistance (OR: 2.437, p=0.025) and MetS clinical manifestations (OR: 3.236, p=0.003). Following the LCD, the increased risk in GG subjects compared with others disappeared (p>0.05). By 32 weeks after dietary therapy (n=84), GG carriers had recovered the risk of metabolic comorbidities (OR: 2.420, p=0.043). This risk was even more evident after 60 weeks (OR: 2.875, p=0.014). These data show an increased risk of insulin resistance and MetS complications in obese subjects of the −11391 GG genotype. The risk was markedly reduced during an energy-restricted diet, but was not sustained. Carriage of the A allele therefore confers protection from weight regain, and the effect is particularly evident 32–60 weeks after the dietary intervention, when improvement in GG subjects had disappeared. Key wordsadiponectininsulin resistancemetabolic syndromeobesity therapypolymorphismweight lossweight regulation
pub© Georg Thieme Verlag KG Stuttgart · New York
doi10.1055/s-0028-1087204
pages55-61
date2009-01